Nat. Rev. Urol. doi: /nrurol

Slides:



Advertisements
Similar presentations
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advertisements

Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
PSA Shared Care Jim Wood. Background A significant number of men with prostate cancer (CaP) are receiving regular hospital follow up (out- patient visits),
What’s new in PCA... Steven Joniau University Hospitals Leuven, Belgium EAU Guidelines 2010 update.
Nat. Rev. Urol. doi: /nrurol
The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:
Volume 4, Issue 5, Pages (September 2017)
Nat. Rev. Urol. doi: /nrurol
Figure 4 Types of urinary diversion
Nat. Rev. Urol. doi: /nrurol
Figure 2 Recruitment of experts to the Delphi study
Nat. Rev. Urol. doi: /nrurol
Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology
Nat. Rev. Urol. doi: /nrurol
Advances in the Treatment of Metastatic Prostate Cancer
Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Representative images from a right radical
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
Figure 1 Key elements of the proposed modified Delphi study
Nat. Rev. Urol. doi: /nrurol
Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.
Nat. Rev. Urol. doi: /nrurol
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Volume 73, Issue 2, Pages (February 2018)
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 2 Schema for the phase II Randomized Observation versus
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Figure 1 The development process of the Asian
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Figure 1 Differences in bladder cancer between genders
therapy and to block androgen action
Nat. Rev. Urol. doi: /nrurol
Figure 3 Treatment algorithm for adult infertile men with varicoceles
Figure 3 Algorithm for the determination of the clinical
Figure 1 Health-care system today
Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.
Nat. Rev. Urol. doi: /nrurol
Figure 2 Temporal summation
Figure 2 Nonmalignant tissue can be spared from radiation
Figure 6 Image sequence demonstrating coronal cuts on MRI
Nat. Rev. Urol. doi: /nrurol
Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.
Nat. Rev. Urol. doi: /nrurol
Active Surveillance for Low Risk Prostate Cancer
Figure 3 Template for standard pelvic lymphadenectomy
Nat. Rev. Urol. doi: /nrurol
the SNP profile using 26 prostate cancer GWAS risk SNPs
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Long-Term Hormonal Therapy: Who Would Benefit?
Figure 2 The evolution of brachytherapy for prostate cancer
Nat. Rev. Urol. doi: /nrurol
Figure 4 The grey zone between active
Nat. Rev. Cardiol. doi: /nrcardio
Axel Heidenreich  European Urology Supplements 
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Axel Heidenreich  European Urology Supplements 
Figure 4 Algorithm for when to determine PTEN
Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.45 Figure 1 Recent years have seen a surge in the use of AS for patients with low-risk (CAPRA 0–2) prostate cancer, from a low of 6.7% between 1990 and 2009 to 40.4% between 2010 and 2013 Figure 1 | Recent years have seen a surge in the use of AS for patients with low-risk (CAPRA 0–2) prostate cancer, from a low of 6.7% between 1990 and 2009 to 40.4% between 2010 and 2013. Conservative management is also being used for patients with intermediate-risk (CAPRA 3–5) disease in 7.6% of cases. Appropriate care delivery for high-risk prostate cancer (CAPRA 6–10) has also changed during this period, with a reduction in the inappropriate use of primary androgen deprivation therapy and an increase in radical prostatectomy (from 25.3% to 53.3% of high-risk cancers). AS, active surveillance; CAPRA, UCSF Cancer of the Prostate Risk Assessment Score; PADT, primary androgen deprivation therapy; RP, radical prostatectomy; RT, radiation therapy; WW, watchful waiting. Figure courtesy of Dr Matt Cooperberg and based on data from recent CaPSURE update10. Permission obtained from Nature Publishing Group © Murphy, D. G. & Loeb, S. Nat. Rev. Urol. 12, 604–605 (2015). Tosoian, J. J. et al. (2016) Active surveillance for prostate cancer: current evidence and contemporary state of practice Nat. Rev. Urol. doi:10.1038/nrurol.2016.45